#1 Clinical Trials Search in Europe

Oxygen Ph.eur.

Recent clinical trials are investigating the use of Oxygen Ph.eur. in premature infants to improve their health outcomes and development. These studies focus on determining the optimal oxygen concentration for resuscitation at birth and exploring automatic oxygen control systems. The research aims to enhance neurodevelopmental outcomes, reduce complications associated with prematurity, and potentially decrease mortality rates in this vulnerable population.

Table of Contents

What is OXYGEN PH.EUR.?

OXYGEN PH.EUR., also known as Medical Oxygen, is a medicinal gas used in healthcare settings, particularly for premature infants[1]. It is a compressed gas that contains pure oxygen, which is essential for breathing and maintaining life. The term “PH.EUR.” stands for “European Pharmacopoeia,” indicating that the oxygen meets specific quality standards for medical use in Europe.

Medical Uses

OXYGEN PH.EUR. is primarily used in the treatment of premature infants, especially those born between 23 and 28 weeks of gestation[1][2]. These extremely preterm infants often require respiratory support due to their underdeveloped lungs. The medical oxygen helps in:

  • Supporting breathing and preventing apnea (temporary pauses in breathing)[2]
  • Maintaining adequate oxygen levels in the blood
  • Assisting with various forms of respiratory support, such as mechanical ventilation or continuous positive airway pressure (CPAP)[2]

Administration

OXYGEN PH.EUR. is administered through inhalation[1]. In premature infants, it is typically delivered through specialized equipment such as ventilators or CPAP machines. The concentration of oxygen can be adjusted based on the infant’s needs, ranging from 21% (room air) up to 100% pure oxygen[1][2].

Ongoing Research

Several clinical trials are currently investigating the optimal use of OXYGEN PH.EUR. in premature infants. These studies aim to improve outcomes and reduce potential complications associated with oxygen therapy. Two notable trials include:

  1. The HiLo-Trial: This study compares the effects of using 30% versus 60% oxygen concentration at birth on neurodevelopmental outcomes in very low birthweight infants[1]. The researchers are investigating whether higher or lower initial oxygen levels can improve development at 18-24 months of age.

  2. Closed-loop Automatic Control Trial: This research evaluates the effectiveness of an automatic system for controlling oxygen levels in extremely preterm infants, compared to manual adjustments[2]. The study aims to determine if this automated approach can reduce complications and improve outcomes.

Potential Benefits and Risks

While OXYGEN PH.EUR. is crucial for the survival of many premature infants, its use must be carefully balanced. Potential benefits include:

  • Improved survival rates
  • Better neurodevelopmental outcomes
  • Support for underdeveloped lungs

However, there are also risks associated with oxygen therapy, which researchers are trying to minimize. These potential complications include:

  • Retinopathy of prematurity (ROP): An eye disorder that can lead to vision problems[1][2]
  • Bronchopulmonary dysplasia (BPD): A chronic lung condition in premature infants[1][2]
  • Necrotizing enterocolitis (NEC): A serious intestinal condition[2]

Conclusion

OXYGEN PH.EUR. plays a vital role in the care of premature infants, supporting their breathing and development. Ongoing research aims to optimize its use, balancing the benefits of oxygen therapy with potential risks. As medical knowledge advances, the goal is to provide the best possible outcomes for these vulnerable patients.

Aspect Details
Study Population Premature infants born between 23-28 weeks gestation
Main Objectives Evaluate effects of different oxygen concentrations and automatic oxygen control on neurodevelopmental outcomes and complications of prematurity
Primary Outcomes Mortality, neurodevelopmental impairment, severe retinopathy of prematurity, chronic lung disease, necrotizing enterocolitis
Intervention Comparison of 30% vs 60% oxygen at birth; Closed-loop automatic control of oxygen vs manual adjustments
Follow-up Period 18-24 months corrected age
Potential Benefits Improved neurodevelopmental outcomes, reduced complications, potentially decreased mortality

FAQ

  • What is Oxygen Ph.eur. and why is it being studied in premature infants? Oxygen Ph.eur. is a medical-grade oxygen used in hospitals. It's being studied in premature infants to determine the best oxygen levels for resuscitation at birth and to improve their overall health outcomes, including brain development and survival rates.
  • What are the main goals of these clinical trials? The main goals are to determine if higher or lower oxygen concentrations at birth improve neurodevelopmental outcomes, and to assess the effectiveness of automatic oxygen control systems in reducing complications associated with prematurity, such as lung problems and eye issues.
  • Who can participate in these trials? The trials are focusing on extremely premature infants, typically those born between 23 and 28 weeks of pregnancy. Specific criteria may vary between studies, but generally, infants without major congenital abnormalities are eligible.
  • What are the potential benefits of participating in these trials? Potential benefits include access to advanced oxygen management techniques that may improve neurodevelopmental outcomes, reduce complications of prematurity, and potentially increase survival rates. However, it's important to note that benefits are not guaranteed.
  • How long do these trials last? The duration varies, but many of these trials follow the infants' progress for up to 24 months after their expected due date. This long-term follow-up helps researchers assess the impact of different oxygen management strategies on the infants' development over time.

Ongoing Clinical Trials on Oxygen Ph.eur.

  • Study on the Effects of 30% vs. 60% Oxygen Levels at Birth for Improving Development in Premature Infants

    Recruiting

    1 1 1 1
    Investigated drugs:
    Ireland

  • Study on Automatic Oxygen Control for Extremely Preterm Infants Using Oxygen PH.EUR.

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Oxygen Ph.eur.: A medical-grade oxygen that meets the standards of the European Pharmacopoeia, used in hospitals for various treatments, including respiratory support for premature infants.
  • Neurodevelopmental outcomes: The progress of brain function as a child grows, including areas such as movement, learning, emotions, and behavior.
  • Gestational age: The length of pregnancy from the first day of the last menstrual period to birth, typically measured in weeks and days.
  • Resuscitation: Emergency medical procedures used to help babies breathe and maintain circulation immediately after birth.
  • Bronchopulmonary dysplasia (BPD): A chronic lung condition that can affect premature infants, often resulting from prolonged need for oxygen therapy or mechanical ventilation.
  • Retinopathy of prematurity (ROP): An eye disorder that can occur in premature infants, potentially leading to vision problems or blindness if severe and left untreated.
  • Necrotizing enterocolitis (NEC): A serious intestinal condition that primarily affects premature infants, causing inflammation and potential damage to the intestines.
  • Closed-loop automatic control: A system that automatically adjusts oxygen levels given to an infant based on continuous monitoring of their oxygen saturation.
  • FiO2: Fraction of inspired oxygen, which refers to the concentration of oxygen that a person is breathing.
  • CPAP: Continuous Positive Airway Pressure, a type of respiratory support that helps keep the airways open using mild air pressure.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-30-vs-60-oxygen-levels-at-birth-for-improving-development-in-premature-infants/
  2. http://clinicaltrials.eu/trial/study-on-automatic-oxygen-control-for-extremely-preterm-infants-using-oxygen-ph-eur/